Plasma p-tau217 predicts PET-based pathological staging for precision Alzheimer disease assessment - PubMed
5 days ago
- #Alzheimer's disease
- #biomarkers
- #plasma p-tau217
- Plasma p-tau217 biomarkers show excellent performance in detecting early amyloid (Thal I-II) and intermediate tau (Braak III-IV) stages in Alzheimer's disease.
- The study identified therapeutic window thresholds for plasma p-tau217 between 1.895-5.077 pg/mL, which are consistent across different staging frameworks.
- Plasma p-tau217-based biomarkers accurately reflect PET-based staging, offering an accessible alternative for identifying candidates for disease-modifying therapies.
- The research involved 237 participants from the AD spectrum, utilizing amyloid/tau PET and plasma biomarker analysis.
- The findings suggest that plasma biomarkers can provide precision assessment of Alzheimer's disease pathology without the need for PET imaging.